Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 299

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 299
---
 to $5.82. The exercise price is
subject to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number
of shares of Common Stock issuable upon the exercise of such warrant will also be adjusted so that the aggregate exercise price shall
be the same immediately before and immediately after any such adjustment. However, unlike the Series A Warrants and Series C Warrants,
the warrants issued on January 6, 2025 are not subject to any exercise price reduction or adjustment relating to the timing of shareholder
approval thereof or the pricing of any future offering.

Preferred Warrants

Exercise Price. The
Preferred Warrants will initially be exercisable for cash at an exercise price equal to $1,000.00 per share. The exercise price is subject
to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number of shares
of Series A Preferred Stock issuable upon the exercise of the Preferred Warrant will also be adjusted so that the aggregate exercise
price shall be the same immediately before and immediately after any such adjustment.

Exercise Period.
The Preferred Warrants will expire on the first anniversary of the closing of the initial business combination, or February 14, 2025.

Forced Exercise.
We have the right to require the holders of Preferred Warrants to exercise such Preferred Warrants into up to an aggregate number of
shares of Preferred Stock equal to the holder’s pro rata amount of 2,000 Preferred Shares.

Fundamental Transactions.
The Preferred Warrants prohibit us from entering into specified fundamental transactions unless the successor entity assumes all of our
obligations under the Preferred Warrants under a written agreement before the transaction is completed. Upon specified corporate events,
a holder of Preferred Warrants will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or any
other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event had
the Preferred Warrant been exercised immediately prior to the applicable corporate event.

Anti-Takeover Provisions

Section 203 of the Delaware General Corporation Law

We are subject to Section
203 of the DGCL, which generally prohibits a publicly held Delaware corporation from engaging in any business combination with any interested
stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

| ● | before such date, the board                                                                                                           
 of directors